{
    "nct_id": "NCT03345420",
    "official_title": "NOVEMBER (Novem- (9), BrEast Radiation), A Phase II Trial of a 9 Day Course of Whole Breast Radiotherapy for Early Stage Breast Cancer",
    "inclusion_criteria": "* Histologically confirmed invasive carcinoma and/or ductal carcinoma in situ (DCIS) of the breast\n* Final pathologic Tis, T1-T3, all must be N0 and M0 status.\n* Negative inked histologic margins from lumpectomy, with the exception of a focus of positive margin at the pectoralis fascia\n* Radiation oncologist does not plan to treat regional lymph nodes beyond standard whole breast tangent fields\n* Lumpectomy with negative lymph node on surgical evaluation (Isolated tumor cells in lymph nodes will be permitted). Patients with invasive carcinoma ≥ 70 yrs and with ER+ positive tumor ≤ 2.0cm may enroll without surgical lymph node evaluation, per section 5.1. Patients with Ductal Carcinoma In Situ (DCIS) of the breast only may enroll without surgical lymph node evaluation.\n* Negative serum or urine beta-human chorionic gonadotropin (HCG) in women of child-bearing potential =< 7 days prior to registration\n\n  * A female of childbearing potential is a sexually mature female who has not undergone a hysterectomy or bilateral oophorectomy and has not been naturally postmenopausal for at least 12 consecutive months\n* Women of child-bearing potential must agree to utilize a form of birth control or agree to undergo sexual abstinence during radiation therapy\n* Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status 0-1\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior radiation therapy to the chest, neck or axilla\n* Prior history of ipsilateral breast cancer (invasive disease or DCIS); lobular carcinoma in situ (LCIS) and benign breast disease is allowed\n* History of prior or concurrent contralateral invasive breast cancer; benign breast disease, LCIS or DCIS of contralateral breast is allowed\n* Active collagen vascular diseases, such as: systemic lupus erythematous, scleroderma, or dermatomyositis\n* Significant post lumpectomy complications requiring an unplanned re-operation or admission for intravenous (IV) antibiotics; re-operation for margins evaluation or nodal evaluation is acceptable\n* Co-existing medical conditions with life expectancy < 5 years\n* Other malignancy within 5 years of registration with the exception of basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the cervix\n* Neoadjuvant chemotherapy or adjuvant chemotherapy delivered before radiation\n* Neuroendocrine carcinoma or sarcoma histology\n* Concurrent radiation sensitizing medications concurrent with radiation, per treatment physician",
    "miscellaneous_criteria": ""
}